Qiagen N.v. · NYSE:QGEN
Qiagen — Investor Day (November 2025)
20 slides from Qiagen's investor day presentation, Nov 21, 2025
Slide 1: Deep Dive: Sample Technologies
Deep Dive SAMPLE TECHNOLOGIES ADVANCING OUR LEADERSHIP IN SAMPLE PREPARATION November 21, 2025
Slide 2: #1 in the First Step of Every Molecular Workflow
#1 IN THE FIRST STEP OF EVERY MOLECULAR WORKFLOW Laboratory workflow Differentiated solutions for modular, Valuable Biological Sample PCR integrated workflows molecular sample technologies Fast time to result, scalability insights Critical first step and ease of use dPCR in molecular workflows Platf
Slide 3: QIAGEN Leading the Way in Sample Preparation
QIAGEN LEADING THE WAY IN SAMPLE PREPARATION Comprehensive consumables ANY >350 ANY biological sample different sample kits DNA / RNA portfolio target analytes e.g., tissue, cells, blood, for manual and including variations serum, wastewater automated processing State-of-the-art automation Manual QI
Slide 4: A Portfolio Strategy Built for Growth
A PORTFOLIO STRATEGY BUILT FOR GROWTH INVEST IN HIGH-VALUE AUTOMATION NEW TECHNOLOGIES APPLICATIONS Expanding access to Capturing high-growth Extending QIAGEN's lab automation at every applications with clear leadership into scale and throughput differentiation next-gen opportunities 4
Slide 5: Sample Tech Momentum: Executing on Our Growth Priorities
SAMPLE TECH MOMENTUM: EXECUTING ON OUR GROWTH PRIORITIES >120 mn preparations Why we win Sold to customers per year $642 mn Most trusted brand 2024 net sales Leveraging our leadership in the first lab step >60% of customers Use downstream QIAGEN solutions Automation momentum in addition to Sample te
Slide 6: Most trusted brand
Most trusted brand
Slide 7: Most Trusted Brand Across Customers
MOST TRUSTED BRAND ACROSS CUSTOMERS Building sustainable ecosystems Labs worldwide use QIAGEN 8 of 10 Sample tech solutions(1) (1) 2024 customer survey with 500 participants 7
Slide 8: Automation momentum
Automation momentum
Slide 9: Scaling Automation for the Future
SCALING AUTOMATION FOR THE FUTURE Key initiatives Manual QIAcube Connect EZ2 Connect QIAcube HT QIAsymphony Low-throughput Mid-throughput High-throughput Expand state- of-the-art portfolio NEW NEW NEW QIAmini QIAsymphony QIAsprint Update Connect Connect automation Launch 2026 Launch 2025 Launch 2026
Slide 10: QIAsprint is optimal for our high-throughput requirements
QIAsprint is optimal for our high-throughput requirements in biodistribution research. Klaus Mackeben, Roche Diagnostics GmbH, Germany We were excited to test the QIAsprint. It's user-friendly design and ability to process large sample numbers efficiently is an ideal solution for laboratories like o
Slide 11: With the new QIAsymphony Connect, we want to build on known extraction performance
With the new QIAsymphony Connect, we want to build on known extraction performance and benefit from future proven sample tracking, the integration in our digital infrastructure and faster processing. Jean Martin Billard, Institut de Pathologie et de Génétique, Belgium 11
Slide 12: High-value applications
High-value applications
Slide 13: Driving Growth in Liquid Biopsy
DRIVING GROWTH IN LIQUID BIOPSY Liquid biopsy market segmentation Non-invasive prenatal testing Oncology 59% ~$3 bn(1) NIPT Oncology ~$4-6 bn(3) +10%(2) +35%(2) Cell-free DNA (cfDNA) blood test Analysis of cfDNA tumor markers 33% for genetic risk assessment in for therapy selection and disease pregn
Slide 14: Enabling Microbiome Analysis
ENABLING MICROBIOME ANALYSIS Our customers Our strengths Across research, pharma, Most comprehensive agriculture and applied testing portfolio Broad sample spectrum from From the totality of all Dedicated manual and stool to soil automated solutions microbes to a subset of Explore microbiome diversi
Slide 15: New technologies
New technologies
Slide 16: Extending Our Sample Tech Leadership with Single-Cell Solutions
EXTENDING OUR SAMPLE TECH LEADERSHIP WITH SINGLE-CELL SOLUTIONS Driving the next wave of growth ~$2.1 bn Expanding Expected single-cell market by 2029 Key applications in oncology, immunology and neurology ~10% CAGR AI-driven 2024 - 2029 Generates data fueling AI-powered drug discovery 3,000+ Adopte
Slide 17: Parse Biosciences – Transforming Single-Cell Research with the Evercode Solution
PARSE BIOSCIENCES – TRANSFORMING SINGLE-CELL RESEARCH WITH THE EVERCODE SOLUTION Data analysis Cells Single-cell prep Sequencing and visualization Challenge How Parse transforms single-cell research Trillions of cells in the body Scalable to billions Largest public dataset of cells supporting the sh
Slide 18: Sample Tech: The Gateway to Downstream Growth
SAMPLE TECH: THE GATEWAY TO DOWNSTREAM GROWTH Renowned multinational lab Sample to Insight Started collaboration with manual Sample technology kits Sample Data analysis and PCR, dPCR, NGS preparation interpretation Sample Sample PCR / dPCR NGS QDI Insights Transitioned to automation for urine and st
Slide 19: Sample Technologies: Advancing Our Leadership in Sample Preparation
SAMPLE TECHNOLOGIES: ADVANCING OUR LEADERSHIP IN SAMPLE PREPARATION Building on most trusted brand Established Leveraging our leadership in the first lab step as the trusted foundation for molecular workflows Driving automation momentum Engineered Converting manual workflows into automation across a
Slide 20: Sample Technologies
SAMPLE TECHNOLOGIES ADVANCING OUR LEADERSHIP IN SAMPLE PREPARATION